Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: Analysis of the UK Medical Research Council AML 10 Trial

European Journal of Cancer

Volumn 40, Issue 7, 2004, Pages 971-978

  Watson, M ^a   Buck, G ^b   Wheatley, K ^c   Homewood, J R ^a   Goldstone, A H ^d   Rees, J K H ^e   Burnett, A K ^f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Bone marrow transplantation; MRC AML10 trial; Quality of Life

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPETENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEISURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL DYSFUNCTION; SOCIOPATHY; UNITED KINGDOM; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COGNITION DISORDERS; COST OF ILLNESS; FATIGUE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TRANSPLANTATION, HOMOLOGOUS;

EID: 1942421662     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00628-2     Document Type: Article

References (23)

1. Watson M., Wheatley K., Harrison G.A.et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone. analysis of the MRC AML 10 trial Cancer. 86:1999;1231-1239.
2. Burnett A.K. Transplantation in first remission of acute myeloid leukemia. New Engl. J. Med. 339:1998;1698-1700.
3. Burnett A.K. Current controversies. which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - an adult treater's view Br. J. Haematol. 118:2002;357-364.
4. Burnett A.K., Wheatley K., Goldstone A.H.et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse. results of the UK MRC AML10 trial' Br. J. Haemat. 118:2002;385-400.
5. Burnett A.K., Wheatley K., Stevens R.F., Goldstone A.H.et al. Further data to question the use of allo BMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patinets under 44 years with donors available. Blood. 100:2002;. (abstr 269).
6. Wellisch D.K., Centeno J., Guzman J., Belin T., Schiller G.J. Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors. Psychosomatics. 37:1996;144-154.
7. Edman L., Larsen J., Hagglund H., Gardulf A. Health-related quality of life, symptom distress and sense of coherence in adult survivors of allogeneic stem-cell transplantation. Eur. J. Cancer Care. 10:2001;124-130.
8. Patrick D.L., Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med. Care. 27(Suppl.):1989;S217- S232.
9. Wright J.G. Outcomes research. what to measure World J. Surg. 23:1999;1224-1226.
10. Zittoun R., Suciu S., Watson M.et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy. a cross-sectional study of the EORTC-GIMEMA AML 8A trial Bone Marrow Transplant. 20:1997;307-315.
11. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organization for Research and Treatment of Cancer QLQ-C30. a quality-of-life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85:1993;365-376.
12. Watson M., Zittoun R., Hall E., Solbu G., Wheatley K. A modular questionnaire for the assessment of longterm quality of life in leukaemia patients. the MRC/EORTC QLQ-LEU Qual. Life Res. 5:1996;15-19.
13. Ringdal G.I., Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual. Life Res. 2:1993;129-140.
14. Busch N.E.H.M., Donaldson G., Sullivan K.M. Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc. Sci. Med. 40:1995;479-490.
15. Fayers P.M., Aaronson N.K., Bjordal K., Sullivan K.M. EORTC QLQ Scoring Manual. 2nd edn. 2001;EORTC, Brussels.
16. Hengeveld M.W., Houtman R.B., Zwaan F.E. Psychological aspects of bone marrow transplantation. a retrospective study of 17 long-term survivors Bone Marrow Transplant. 3:1988;69-75.
17. Heinonen H., Volin L., Uutela A., Zevon M., Barrick C., Ruutu T. Gender-associated differences in the quality of life after allogeneic BMT. Bone Marrow Transplant. 28:2001;503-509.
18. Andrykowski M.A., Henslee P.J., Farrall M.G. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant. 4:1989;75-81.
19. Litwins N.M., Rodrigue J.R., Weiner R.S. Quality of life in adult recipients of bone marrow transplantation. Psychol. Rep. 1:1994;323-328.
20. Molassiotis A., Morris P.J. Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nurs. 22:1999;340-349.
21. Broers S., Kaptein A.A., Le Cessie S., Fibbe W., Hengeveld M.W. Psychological functioning and quality of life following bone marrow transplantation. a 3-year follow-up study J. Psychosom. Res. 48:2000;11-21.
22. Burnett A.K., Goldstone A.H., Stevens R.M.et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission. results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties Lancet. 351:1998;700-708.
23. Burnett A.K., Wheatley K., Goldstone A.H.et al. A comparison of ADE vs MAE and S-DAT vs H-DAT retinoic acid for induction and four vs five total courses using chemotherapy or stem cell transplant in consolidation, in 3549 patients under 60 years old with AML. Blood. 100:2002;. (abstr. 582).